Celgene Corp. buy matumba
Start price
22.10.11
/
50%
€24.05
Target price
28.12.11
€26.08
Performance (%)
8.41%
End price
28.12.11
€26.08
Summary
This prediction ended on 28.12.11 with a price of €26.08. The BUY prediction by matumba finished with a performance of 8.41%. matumba has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celgene Corp. | - | - | - | - |
| iShares Core DAX® | 0.410% | -2.543% | 14.415% | 14.709% |
| iShares Nasdaq 100 | -2.154% | 4.721% | 33.222% | 52.436% |
| iShares Nikkei 225® | -0.066% | -0.307% | 8.496% | 3.743% |
| iShares S&P 500 | -0.527% | 3.848% | 28.621% | 47.348% |
Comments by matumba for this prediction
In the thread Celgene Corp. diskutieren
risikobereit?
Revlimid Präparat gegen Krebs soll 2012 ein Umsatzplus von 30% bringen (3,15MRD Dollar)
Europ. Arzneimittelagentur hat sich positiv geäußert- dies ermögl. gute Chancen